logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10639366 B1

PDFFull Text
Date of Patent:
May. 05, 2020

Filed:

Feb. 25, 2016

Use of inactivated nonreplicating modified vaccinia virus ankara (mva) as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors

Applicant:

Memorial Sloan-kettering Cancer Center, New York, NY (US);

Inventors:

Liang Deng, New York, NY (US);

Stewart Shuman, New York, NY (US);

Jedd D. Wolchok, New York, NY (US);

Taha Merghoub, New York, NY (US);

Peihong Dai, New York, NY (US);

Weiyi Wang, New York, NY (US);

Assignee:

Memorial Sloan Kettering Cancer Center, New York, NY (US);

Attorney:

Foley & Lardner LLP

Primary Examiner:

Michelle S Horning

Int. Cl.
CPC ...
A61K 39/12 (2006.01); A61K 39/285 (2006.01); A61K 39/395 (2006.01); A61K 39/00 (2006.01); C07K 16/28 (2006.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
A61K 39/285 (2013.01); A61K 39/0011 (2013.01); A61K 39/12 (2013.01); A61K 39/39541 (2013.01); A61K 39/39558 (2013.01); A61K 45/06 (2013.01); C07K 16/2818 (2013.01); C07K 16/2827 (2013.01); A61K 2039/505 (2013.01); A61K 2039/5252 (2013.01); A61K 2039/54 (2013.01); A61K 2039/585 (2013.01); C07K 2317/76 (2013.01); C12N 2710/24132 (2013.01); C12N 2710/24134 (2013.01);
Abstract

The present disclosure relates to infection-competent, but nonreplicative inactivated modified vaccinia Ankara (MVA) and its use as immunotherapy, alone, or in combination with immune checkpoint blocking agents for the treatment of malignant solid tumors. Particular embodiments relate to inducing an immune response in a subject diagnosed with a solid malignant tumor.

Find Patent Forward Citations

Deng, Liang. (2020). Use of inactivated nonreplicating modified vaccinia virus ankara (mva) as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors (U.S. Patent No. 10639366). U.S. Patent and Trademark Office. https://idiyas.com/patent/badge/10639366

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Loading…